dc.creator | Liakopoulos V., Nikitidou O., Kalathas T., Roumeliotis S., Salmas M., Eleftheriadis T. | en |
dc.date.accessioned | 2023-01-31T08:50:15Z | |
dc.date.available | 2023-01-31T08:50:15Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1007/s11255-017-1632-9 | |
dc.identifier.issn | 03011623 | |
dc.identifier.uri | http://hdl.handle.net/11615/75808 | |
dc.description.abstract | In 2016, the International Society of Peritoneal Dialysis (ISPD) published guidelines that focus on the importance of both prevention and treatment of peritonitis. For once more, the need for annual reporting of peritonitis rates and recording of peritonitis and exit-site infections, isolated microorganism and antimicrobial susceptibilities as a central component of a quality improvement program is highlighted. Data on new antibiotic regimens, techniques for microorganism isolation and peritoneal dialysis solutions are included. Training of both peritoneal dialysis nurses and patients seems to be crucial, while the modifiable risk factors for peritonitis seem to be of great interest. In this article, we record the changes in the last ISPD (2016) guidelines compared to the previous ones published in 2010. © 2017, Springer Science+Business Media Dordrecht. | en |
dc.language.iso | en | en |
dc.source | International Urology and Nephrology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020123656&doi=10.1007%2fs11255-017-1632-9&partnerID=40&md5=3566560c71730804594468d579933ceb | |
dc.subject | aminoglycoside antibiotic agent | en |
dc.subject | cephalosporin derivative | en |
dc.subject | ciprofloxacin | en |
dc.subject | fluconazole | en |
dc.subject | gentamicin | en |
dc.subject | nystatin | en |
dc.subject | pseudomonic acid | en |
dc.subject | rifampicin | en |
dc.subject | antifungal agent | en |
dc.subject | antiinfective agent | en |
dc.subject | antibiotic prophylaxis | en |
dc.subject | automation | en |
dc.subject | bacterium culture | en |
dc.subject | catheter removal | en |
dc.subject | catheterization | en |
dc.subject | continuous ambulatory peritoneal dialysis | en |
dc.subject | Gram negative infection | en |
dc.subject | Gram positive infection | en |
dc.subject | health program | en |
dc.subject | human | en |
dc.subject | infection risk | en |
dc.subject | medical society | en |
dc.subject | mycosis | en |
dc.subject | non tuberculous mycobacterial peritonitis | en |
dc.subject | nonhuman | en |
dc.subject | peritoneal dialysis | en |
dc.subject | peritonitis | en |
dc.subject | practice guideline | en |
dc.subject | prognosis | en |
dc.subject | Review | en |
dc.subject | risk factor | en |
dc.subject | Staphylococcus aureus | en |
dc.subject | Staphylococcus infection | en |
dc.subject | tuberculous peritonitis | en |
dc.subject | complication | en |
dc.subject | Gram negative infection | en |
dc.subject | Gram positive infection | en |
dc.subject | microbiology | en |
dc.subject | mixed infection | en |
dc.subject | mycosis | en |
dc.subject | peritoneal dialysis | en |
dc.subject | peritonitis | en |
dc.subject | practice guideline | en |
dc.subject | Anti-Bacterial Agents | en |
dc.subject | Antifungal Agents | en |
dc.subject | Coinfection | en |
dc.subject | Gram-Negative Bacterial Infections | en |
dc.subject | Gram-Positive Bacterial Infections | en |
dc.subject | Humans | en |
dc.subject | Mycoses | en |
dc.subject | Peritoneal Dialysis | en |
dc.subject | Peritonitis | en |
dc.subject | Practice Guidelines as Topic | en |
dc.subject | Springer Netherlands | en |
dc.title | Peritoneal dialysis-related infections recommendations: 2016 update. What is new? | en |
dc.type | other | en |